Emerging Economies in a Critical Financial Crisis Situation

The financial condition in the emerging economies worsened as their foreign currency debt is ranging between 20 percent and 50 percent of GDP. The stress on emerging market was building since 2013. Taper tantrum, a term coined by Morgan Stanley to describe the vulnerability of capital outflows faced by fragile five nations namely Brazil, India, Indonesia, Turkey and South Africa. Growth disguised the underlying challenges, low current account deficits, monetary accommodation, and drawing more capital are key factors seen in those markets.

The prevailing conditions of misallocation of capital in uneconomic high-end projects or financial speculation have created a textbook recipe for an emerging market crisis demanding a large amount of debt, coupled with domestic credit bubble. The critical financial situation in emerging economies is surged with a budget deficit, weak banking sector, current account gaps, inadequate forex reserves, and considerable short term foreign currency debt. Moreover, reliance on commodity exports, narrowly based industrial structures, corruption, institutional weaknesses, and miserable political and economic leadership have worsened the financial situation in these economies.

The total borrowing of the emerging markets have increased from US$21 trillion in 2007 to US$63 trillion in 2017. Moreover, since 2007, the foreign-currency debt – in euros, dollars, and yen – of these countries doubled to around $9 trillion. India, China, Indonesia, South Africa, Malaysia, Chile, Brazil, Mexico, and some Eastern European countries have foreign-currency debt between 20 percent and 50 percent of GDP.

Crohn’s Disease Therapeutics Sector Shows a Promising Drug Pipeline

San Francisco, California, Sept 04, 2018: According to a recent market research report by TMR Research, the global market for Crohn’s disease therapeutics market has seen a splendid rise in the past few years owing to the vast rise in prevalence of the condition over the past few years; researchers are attributing the rising prevalence of the conditions to factors such as rapid industrialization, increased presence of hazardous environmental conditions, and high exposure to bare sunlight. The report is titled “Crohn’s Disease Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018–2028.”

Get Sample Copy of this Report @ 


In response to the rising therapeutic needs for patients affected by Crohn’s disease, a number of new companies have forayed into the market, ploughing increased resources and funds towards R&D activities aimed at the development of an effective cure. Research activities are also ripe in the field of generics and biosimilars and companies are putting in efforts to reach out to a larger patient pool through cost-effective medicines. The dynamic nature of the global Crohn’s disease therapeutics market is visible from the large pipeline of promising drugs for the treatment of the condition.

From a geographical standpoint, the market for Crohn’s disease therapeutics acquires a large share of its revenue from the North America regional market. The factors that work in favor of the regional market include a well-established healthcare sector, vast funds pumped into R&D activities aimed at the development of new therapies for the condition, and the rising patient pool. Moreover, the encouraging regulations pertaining to the provision of medical reimbursement and the high population of people having medical insurance also work well for the regional market.

Read Comprehensive Overview of Report @


Over the years, the vendor landscape of the global Crohn’s disease therapeutics market has become increasingly populated owing to the increased focus of a number of leading pharmaceutical companies on the sector. Some of the leading companies in the market are Genentech Inc., Pfizer Inc., Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, Allergan, Perrigo Company PLC, Celgene Corporation, AbbVie Inc., Salix Pharmaceuticals, and UCB India Private Limited.